e-therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for e-therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 34.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Jan 05
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Sep 13e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Mar 27We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Jul 07We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn
Oct 28Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?
Mar 21We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Feb 14Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?
Jan 10
Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?
Dec 06In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as e-therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 7/31/2023 | 0 | -10 | -10 | -10 | N/A |
| 4/30/2023 | 0 | -9 | -9 | -9 | N/A |
| 1/31/2023 | 0 | -8 | -8 | -8 | N/A |
| 10/31/2022 | 0 | -9 | -9 | -9 | N/A |
| 7/31/2022 | 0 | -9 | -10 | -9 | N/A |
| 4/30/2022 | 0 | -9 | -9 | -9 | N/A |
| 1/31/2022 | 0 | -8 | -8 | -8 | N/A |
| 10/31/2021 | 1 | -6 | -6 | -6 | N/A |
| 7/31/2021 | 1 | -4 | -5 | -5 | N/A |
| 4/30/2021 | 1 | -4 | -4 | -4 | N/A |
| 1/31/2021 | 0 | -4 | -3 | -3 | N/A |
| 10/31/2020 | 0 | -4 | -3 | -3 | N/A |
| 7/31/2020 | 0 | -3 | -3 | -3 | N/A |
| 4/30/2020 | 0 | -3 | -3 | -3 | N/A |
| 1/31/2020 | 0 | -2 | -2 | -2 | N/A |
| 10/31/2019 | 0 | -3 | -2 | -2 | N/A |
| 7/31/2019 | 0 | -3 | -2 | -2 | N/A |
| 4/30/2019 | 0 | -4 | -3 | -3 | N/A |
| 1/31/2019 | 0 | -4 | -4 | -4 | N/A |
| 10/31/2018 | 0 | -4 | -4 | -4 | N/A |
| 7/31/2018 | N/A | -5 | -5 | -5 | N/A |
| 4/30/2018 | N/A | -5 | -5 | -5 | N/A |
| 1/31/2018 | N/A | -5 | -4 | -4 | N/A |
| 10/31/2017 | N/A | -7 | -6 | -6 | N/A |
| 7/31/2017 | N/A | -8 | -7 | -7 | N/A |
| 4/30/2017 | N/A | -11 | N/A | -8 | N/A |
| 1/31/2017 | N/A | -13 | N/A | -9 | N/A |
| 10/31/2016 | N/A | -13 | N/A | -9 | N/A |
| 7/31/2016 | N/A | -12 | N/A | -9 | N/A |
| 4/30/2016 | N/A | -11 | N/A | -9 | N/A |
| 1/31/2016 | N/A | -9 | N/A | -9 | N/A |
| 10/31/2015 | N/A | -8 | N/A | -8 | N/A |
| 7/31/2015 | N/A | -8 | N/A | -7 | N/A |
| 4/30/2015 | N/A | -8 | N/A | -8 | N/A |
| 1/31/2015 | N/A | -8 | N/A | -10 | N/A |
| 10/31/2014 | N/A | -7 | N/A | -9 | N/A |
| 7/31/2014 | N/A | -7 | N/A | -9 | N/A |
| 4/30/2014 | N/A | -6 | N/A | -7 | N/A |
| 1/31/2014 | N/A | -5 | N/A | -6 | N/A |
| 10/31/2013 | N/A | -5 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ETX's forecast earnings growth is above the savings rate (1.8%).
Earnings vs Market: Insufficient data to determine if ETX's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if ETX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ETX's revenue is forecast to grow faster than the UK market.
High Growth Revenue: Insufficient data to determine if ETX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ETX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/10 12:44 |
| End of Day Share Price | 2024/05/08 00:00 |
| Earnings | 2023/07/31 |
| Annual Earnings | 2023/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
e-therapeutics plc is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Philip Morrish | Growth Equities & Company Research |
| Paul Cuddon | Numis Securities Ltd. |
| Savvas Neophitou | Panmure Liberum Historic (Panmure Gordon) |